Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers

Colorectal cancer testing detected tumor DNA before all observed clinical recurrences, with a median lead time of four months.

Rhea-AI Summary

Myriad Genetics (MYGN) released new MONSTAR-SCREEN-3 study data on post-surgical residual cancer detection in resectable colorectal and pancreatic cancers. The ongoing study evaluates Precise MRD, a whole-genome sequencing-based test for molecular residual disease, or cancer traces remaining after treatment.

In colorectal cancer, circulating tumor DNA detected one month after surgery was associated with disease progression. Detection preceded all observed clinical recurrences by a median four months; more than half of post-surgical positive patients were detected below 100 parts per million. Initial pancreatic cancer findings showed significantly worse recurrence-free survival in patients with detectable residual disease one month after surgery than in those without it. Myriad said the results support the test's potential for earlier risk assessment.

Positive

• Minor pointColorectal cancer ctDNA detection preceded all observed recurrence events, with a median lead time of four months.
• Minor pointColorectal cancer ctDNA detected one month after surgery was strongly associated with disease progression.
• Minor pointMore than half of post-surgical ctDNA-positive colorectal cancer patients were identified below 100 parts per million.
• Minor pointPancreatic cancer residual disease detection at one month post-surgery distinguished patients with significantly worse recurrence-free survival.
• Minor pointPersonalized pancreatic cancer panels were created for all evaluable patients; half achieved the maximum 1,000-variant panel.

Negative

• None.

Key Figures

Median lead time: 4 months Ultra-sensitive ctDNA level: Below 100 parts per million Personalized panel creation: All evaluable patients +1 more

Median lead time

4 months

ctDNA detection before clinical recurrence in observed colorectal cancer recurrence events

Ultra-sensitive ctDNA level

Below 100 parts per million

More than half of post-surgical ctDNA-positive patients

Personalized panel creation

All evaluable patients

Resectable pancreatic cancer

Maximum panel size

1,000 variants

Half of patients achieved the maximum panel

Key Terms

whole-genome sequencing, molecular residual disease, ctdna, recurrence-free survival, +1 more

5 terms

whole-genome sequencing technical

"its whole-genome sequencing (WGS)-based Precise MRD™ platform"

Whole-genome sequencing is the process of reading an organism’s entire DNA instruction manual to capture all genetic information rather than just selected parts. For investors, it matters because having the full genetic picture can reveal new diagnostics, drug targets, or personalized treatments that drive product value, regulatory approvals, and long-term revenue potential, while improvements in speed and cost can expand market reach like making a complex map easier and cheaper to produce.

molecular residual disease medical

"ultra-sensitive molecular residual disease (MRD) detection"

Molecular residual disease is the tiny amount of cancer that can remain in the body after treatment and is detectable only by sensitive tests that find cancer DNA or other molecular traces. It matters to investors because these measurements can predict relapse, guide whether additional therapy is needed, and shape the market for diagnostics and drugs—much like finding embers after a fire helps decide if more firefighting is required.

ctdna medical

"ctDNA detected prior to clinical recurrence in all observed recurrence events"

Circulating tumor DNA (ctDNA) is tiny fragments of genetic material shed by cancer cells into the bloodstream, like breadcrumbs that can reveal a tumor’s presence and genetic makeup without needing a biopsy. For investors, ctDNA matters because tests and technologies that detect and analyze these fragments can speed diagnosis, track treatment response, and signal relapse, creating commercial opportunities in diagnostics, personalized therapies, and monitoring services.

recurrence-free survival medical

"significantly worse recurrence-free survival than those without detectable MRD"

Recurrence-free survival is the length of time after a treatment during which a patient shows no return of disease. It’s used in clinical trials to measure how well a therapy prevents the illness from coming back — think of it like the time a repaired roof stays leak-free. For investors, longer recurrence-free survival suggests a treatment is more effective, which can improve chances of regulatory approval, commercial uptake, and long-term revenue.

resectable medical

"patients with resectable colorectal and pancreatic cancers"

Able to be removed surgically: when a tumor or diseased tissue is described as resectable, surgeons judge that it can be removed by an operation with the goal of removing all visible disease (often aiming for clear margins) based on its size, location, involvement of nearby structures, and the patient’s overall condition. The term reflects technical and clinical feasibility rather than a guarantee of cure and is contrasted with “unresectable,” which means surgery is not considered a viable option because of risk, spread, or anatomical constraints.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Data from ongoing study supports the potential clinical utility of whole-genome sequencing-based Precise MRD™ to identify recurrence risk and detect disease earlier following surgery

SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces new data from the ongoing MONSTAR-SCREEN-3 study demonstrating the potential of its whole-genome sequencing (WGS)-based Precise MRD™ platform to support ultra-sensitive molecular residual disease (MRD) detection in patients with resectable colorectal and pancreatic cancers.

The findings, which will be presented as part of the European Society for Medical Oncology (ESMO) Congress 2026, reinforce the role of highly sensitive MRD testing after curative-intent surgery in tumor types where earlier insight into recurrence risk may help inform monitoring and treatment decisions.

“These data reinforce the potential of Precise MRD to bring more sensitive, personalized monitoring to cancers where recurrence can be difficult to identify until disease burden is higher,” said Dale Muzzey, Ph.D., Chief Scientific Officer, Myriad Genetics. “By leveraging whole-genome sequencing to build individualized panels capable of detecting ctDNA at very low levels, Precise MRD may help clinicians identify recurrence risk earlier and make more informed decisions about patient management following surgery.”

New MONSTAR-SCREEN-3 Data Support Utility of Ultra-Sensitive MRD Detection Across Colorectal and Pancreatic Cancers

The MONSTAR-SCREEN-3 data highlight the performance of Myriad's WGS-based Precise MRD platform in two high-need settings: resectable colorectal cancer and resectable pancreatic cancer. The study evaluated whether personalized, ultra-sensitive MRD testing could identify patients at higher risk of recurrence following surgery and provide earlier molecular insight than conventional clinical surveillance.

In patients with resectable colorectal cancer, ctDNA detected one month after surgery was strongly associated with disease progression. ctDNA was detected prior to clinical recurrence in all observed recurrence events, with a median lead time of four months. More than half of post-surgical ctDNA-positive patients were identified at ultra-sensitive levels, i.e., below 100 parts per million.

Researchers also reported initial findings in patients with resectable pancreatic cancer, a low-shedding tumor type in which ctDNA detection has historically been challenging. Personalized panel creation was successful for all evaluable patients, with half achieving the maximum 1,000-variant panel. Patients with MRD detected one month after surgery had significantly worse recurrence-free survival than those without detectable MRD, supporting further evaluation of WGS-based MRD testing in this high-need setting.

“Together, these findings add to a growing body of evidence supporting ultra-sensitive MRD detection as a tool to improve post-surgical risk stratification and disease monitoring,” said Takayuki Yoshino, MD, PhD, National Cancer Center Hospital East and principal investigator of the MONSTAR-SCREEN-3 study. “The consistent association between post-operative ctDNA detection and patient outcomes, coupled with the ability to identify recurrence months before conventional methods, highlights the potential clinical value of ultra-sensitive MRD assessment for guiding follow-up strategies in patients with resectable cancers.”

The MONSTAR-SCREEN-3 findings will be featured in the following ESMO presentations:

Clinical Significance of Ultrasensitive ctDNA Detection for Molecular Residual Disease Assessment in Resectable Colorectal Cancer in MONSTAR-SCREEN-3

Session: Proffered Paper 1: Basic Science and Translational Research
Room: Burgos Auditorium - Hall 3
Date: Sunday, October 25, 2026
Time 2:45 -4:15pm

Molecular Residual Disease Detection for Resectable Pancreatic Cancer Using a Whole-Genome Sequencing-Based ctDNA Assay: Initial Findings from MONSTAR-SCREEN-3
Poster Number: 3138P
Date: Sunday, October 25, 2026
Time 12:00 -12:45pm

About Myriad Genetics 
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit www.myriad.com. 

Myriad Genetics Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential of Precise MRD to detect molecular residual disease and identify recurrence risk in resectable colorectal and pancreatic cancers, the potential clinical value of MRD testing, upcoming ESMO Congress 2026 presentations, and the future results of the MONSTAR-SCREEN-3 study and the development, regulatory status and commercialization of Precise MRD. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 24, 2026, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. 

Investor Contact 
Matt Scalo 
(801) 584-3532 
IR@myriad.com 

Media Contact 
Andria Rosell
(385) 202-3510
PR@myriad.com  

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How early did Myriad Genetics' Precise MRD detect colorectal cancer recurrence in MONSTAR-SCREEN-3?

Circulating tumor DNA was detected before clinical recurrence in all observed recurrence events, with a median lead time of four months. Detection one month after surgery was also strongly associated with disease progression.

What did Myriad Genetics report about personalized test panels for pancreatic cancer in MONSTAR-SCREEN-3?

Personalized panel creation succeeded for all evaluable pancreatic cancer patients, with half achieving the maximum 1,000-variant panel. These were initial findings from the ongoing study.